Beleave Inc. is pleased to provide an update on its meeting with the Hamilton Planning Committee on May 14, 2019.
TORONTO, May 15, 2019 /PRNewswire/ - Beleave Inc. (CSE: BE) (OTCQX: BLEVF) (“Beleave” or the “Company”) is pleased to provide an update on its meeting with the Hamilton Planning Committee on May 14, 2019.
The committee unanimously approved Beleave’s request to rezone their facility in Hamilton, Ontario and will reconvene later this month, through a city council meeting the week of May 20, 2019, to finalize the approval for expansion.
Beleave’s Hamilton facility continues to provide high-efficiency extraction, R&D, product development and cultivation of cannabis and cannabis derived products throughout this approval process. The facility’s significant expansion, if approved City Council, will provide the ability to expand its current production capacity.
The Hamilton facility houses growing space for Beleave’s line of cannabis products, and continues to be its main hub for extraction, packaging, and distribution. The proposed expansion will allow the Company to greatly increase the efficiency and productivity of its growing and distribution strategy.
ABOUT BELEAVE INC.
Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully-licenced to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.
Beleave is developing new product lines, including cannabis-infused powder products for 2019 as the recreational market is expected to allow for food and beverage-based cannabis products. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. Through its majority ownership of Procannmed S.A.S., Beleave is fully licensed to cultivate, produce, and extract medical cannabis in Colombia positioning it to capitalize on exports and the expanding Latin American market. The Company has partnered with Canymed GmbH to supply the German market with medical cannabis.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/beleave-receives-unanimous-approval-from-hamilton-planning-committee-300850706.html
SOURCE Beleave Inc.
Company Codes: OTC-QX:BLEVF, CNSX:BE
